Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%

Healthcare

Page 109
  1. Nov 04, 2025 · 16:39 · EPRX

    Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

    01
  2. Nov 04, 2025 · 15:10 · HEM

    Hemostemix Closes Private Placement of $461,230

    Hemostemix Closes Private Placement of $461,230

    02
  3. Nov 04, 2025 · 11:51 · BNXT

    Bionxt receives EU patent grant notice for oral MS film

    Bionxt receives EU patent grant notice for oral MS film

    03
  4. Nov 04, 2025 · 09:01 · TTI

    Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis

    Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis

    04
  5. Nov 04, 2025 · 07:30 · BCT

    BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+(TM) in Breast and Prostate Cancer Models

    BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+(TM) in Breast and Prostate Cancer Models

    05
  6. Nov 04, 2025 · 07:25 · KNE

    Kane Biotech Presents revyve(TM) Data at Diabetic Foot and Southern Region Burn Conferences

    Kane Biotech Presents revyve(TM) Data at Diabetic Foot and Southern Region Burn Conferences

    06
  7. Nov 04, 2025 · 07:00 · 4875

    MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

    MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

    07
  8. Nov 04, 2025 · 03:16 · DTC

    Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models

    Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models

    08
  9. Nov 04, 2025 · 03:05 · BNXT

    BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies

    BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies

    09
  10. Nov 04, 2025 · 00:40 · EKG

    CardioComm Terminates Royalty Agreement and Enters into $512,000 Insider Loan Facility to Advance Gems Flex and 14-Day Holter/LTCM Platform

    CardioComm Terminates Royalty Agreement and Enters into $512,000 Insider Loan Facility to Advance Gems Flex and 14-Day Holter/LTCM Platform

    10
  11. Nov 03, 2025 · 19:13 · AIAI

    Netramark signs NetraAI contract with biopharm firm

    Netramark signs NetraAI contract with biopharm firm

    11
  12. Nov 03, 2025 · 17:54 · CRRX

    CareRx Reports Results for the Third Quarter of 2025

    CareRx Reports Results for the Third Quarter of 2025

    12
  13. Nov 03, 2025 · 16:39 · TLT

    Theralase says X-ray drug effective in cancer models

    Theralase says X-ray drug effective in cancer models

    13
  14. Nov 03, 2025 · 16:04 · NRX

    NurExone Accepted into ARMI's BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing

    NurExone Accepted into ARMI's BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing

    14
← Newer Older →